Private Trust Company’s Arcus Biosciences RCUS Stock Holding History

Private Trust Company’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-57	Closed	-$1K	–	2356
2022 Q4	$1K	Buy	+57	New	+$1.57K	﹤0.01%	2127

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Private Trust Company's RCUS Position: Q1 2023 in Review

Private Trust Company sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 57 shares — an estimated $1K sold.

Private Trust Company first reported a position in RCUS in Q4 2022 and held it in 1 quarter. The position peaked at $1K in Q4 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

Private Trust Company reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
Private Trust Company sold 57 Arcus Biosciences shares in Q1 2023, an estimated $1K.
Private Trust Company first reported a position in Arcus Biosciences in Q4 2022 and held it in 1 quarter.
Private Trust Company's Arcus Biosciences position peaked at $1K in Q4 2022.
179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Private Trust Company's 13F filing for Q1 2023, filed 12 Apr 2023.